Apr 10, 2020 · An ultra-purified, high-concentration galacto-oligosaccharide, RP-G28, is being developed as a treatment for patients with LI. The efficacy and safety of RP-G28 in reducing symptoms of lactose intolerance were assessed in a blinded, randomized, placebo-controlled trial.

RP-G28: 一种微生物调节剂药物，由Ritter GmbH (Ritter GmbH)公司最早进行研发，目前全球最高研发状态为无进展，作用机制: 微生物调节剂，治疗领域: 遗传病与畸形,消化系统疾病,内分泌与代谢疾病。

Apr 10, 2020 · An ultra-purified, high-concentration galacto-oligosaccharide, RP-G28, is being developed as a treatment for patients with LI. The efficacy and safety of RP-G28 in reducing symptoms of lactose intolerance were assessed in a blinded, randomized, placebo-controlled trial.

Jul 18, 2017 · 本研究通过随机、双盲、多点安慰剂对照实验，发现“RP-G28”这种高纯度（>95%）的短链低聚半乳糖（GOS）能够显著改善乳糖吸收和耐受性的临床结果。

Jan 7, 2017 · A randomized, double-blind, multisite placebo-controlled trial conducted in human subjects demonstrated that administration of a highly purified (>95%) short-chain galactooligosaccharide (GOS), designated "RP-G28," significantly improved clinical outcomes for lactose digestion and tolerance.

Jul 13, 2018 · 一项评估 RP-G28 在乳糖不耐症患者中的疗效、持久性、安全性和耐受性的 3 期、多中心、随机、双盲、安慰剂对照、平行组研究. 这是一项在美国 (US) 进行的多中心、随机、双盲、安慰剂对照、平行组研究，旨在评估 RP-G28 与安慰剂相比对减轻乳糖不耐受相关症状的疗效。 本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。 研究人员寻找符合特定描述的人，称为资格标准。 这些标准的一些例子是一个人的一般健康状况或先前的治 …

RP-G28 is novel galacto-oligosaccharide (GOS) being investigated to improve lactose digestion and the symptoms of lactose intolerance in affected patients. A randomized, double-blind, parallel group, placebo-controlled study was conducted at 2 sites in the United States. RP-G28 or placebo was administered to 85 patients with LI for 35 days.

Dec 13, 2013 · RP-G28 is novel galacto-oligosaccharide (GOS) being investigated to improve lactose digestion and the symptoms of lactose intolerance in affected patients. Methods: A randomized, double-blind, parallel group, placebo-controlled study was conducted at 2 …

A novel galacto-oligosaccharide (RP-G28) shifts the human gut microbiota by altering the relative abundance of specific bacteria. These changes remove undigested lactose from the gut, thus reducing the gas production and water secretion that produce LI symptoms.

Apr 10, 2020 · 正在开发一种超纯化，高浓度的低聚半乳糖RP-G28，以治疗LI患者。 在一项盲法，随机，安慰剂对照试验中评估了RP-G28在减轻乳糖不耐症症状方面的功效和安全性。